Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain
DARIOS
1 other identifier
observational
30,181
1 country
11
Brief Summary
The present project is aimed at determining the prevalence of LDL-C \<130 mg/dl with hsCRP ≥2mg/l, and of HDL-C \< 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2009
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 19, 2009
CompletedFirst Posted
Study publicly available on registry
October 20, 2009
CompletedStudy Start
First participant enrolled
November 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedOctober 20, 2011
October 1, 2011
1.9 years
October 19, 2009
October 19, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments
retrospectively
Secondary Outcomes (3)
High sensitivity C reactive protein & CHR risk by Framingham adapted functions
retrospectively
Lipid profile among the Spanish regions, as in the primary outcome variable
retrospectively
Biomarkers: Interleukines 6 and 10, oxidized LDL, VCAM, ICAM, TNF alpha, neopterin, fibrinogen, lp(a), MMP 9 Apo A, Apo B, adiponectin, leptin, resistin, and yet other
prospectively
Study Arms (1)
1
Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
Eligibility Criteria
Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
You may qualify if:
- Have an Informed consent form signed when the patient accepted to participate in the study already performed.
- Spanish population between
- Data from Epidemiological studies performed after the year 2000
You may not qualify if:
- Spanish population outside the age range
- Data from Epidemiological studies performed before the year 2000
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (11)
Research Site
Andalucia, Andalusia, Spain
Research Site
Canarias, Canary Islands, Spain
Research Site
Castilla Y Leon, Castille and León, Spain
Research Site
Talavero, Castille-La Mancha, Spain
Research Site
Girona, Catalonia, Spain
Research Site
Hospitalet, Catalonia, Spain
Research Site
Badajoz, Extremadura, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Mallorca, Mallorca, Spain
Research Site
Murcia, Murcia, Spain
Research Site
Navarra, Navarre, Spain
Biospecimen
No samples will be obtained, but biomarkers will be analysed from frozen serum samples retained by the pervious studies performed.
Study Design
- Study Type
- observational
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 19, 2009
First Posted
October 20, 2009
Study Start
November 1, 2009
Primary Completion
October 1, 2011
Study Completion
October 1, 2011
Last Updated
October 20, 2011
Record last verified: 2011-10